Company intelligence / Profile preview

The GI Company

Framingham, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

The GI Company was a development-stage biopharmaceutical company focused on the discovery and development of prostone-based therapeutics for gastrointestinal and other systemic diseases. The company's primary research centered on the activation of chloride channels to treat conditions such as chronic constipation and irritable bowel syndrome. Its lead development programs included cobiprostone (SPI-8811), a second-generation prostone analog. In 2007, the company was acquired by Sucampo Pharmaceuticals to strengthen its pipeline of gastrointestinal treatments and leverage its expertise in prostone chemistry.

Therapeutic areas: Gastroenterology
Modalities: Small molecule
Industry: Biotech

Partnerships

Sucampo Pharmaceuticals

Beyond the preview

Go deeper on The GI Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on The GI Company.

Explore the full profile